EC Number: 691-729-9
CAS Number: 910463-68-2
IUPAC Name: 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-m
Statut réglementaire: Doses thérapeutiques approuvées de 0,5 mg et 1 mg
Molecular Weight: 4114
Chemical Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Application: Agoniste du récepteur GLP-1 ; adjuvant au régime/exercice pour le contrôle glycémique du diabète de type 2

Autres informations

Description supplémentaire:

This pharmaceutical-grade Semaglutide, supplied but not manufactured by Suzhou Pharmaserve Technology, is indicated to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise, at approved therapeutic doses of 0.5 mg and 1 mg; the supplier notes it works through the incretin pathway, stimulating insulin secretion while delaying gastric emptying and inducing satiety, similar to endogenous GLP-1. It is sold in North America, Western Europe, Australasia, and the Middle East.